EUVIMEDEUVIMED entdecken
Crossref

Combination of Circulating Cell-Free DNA and Positron Emission Tomography to Distinguish Non–Small Cell Lung Cancer from Tuberculosis

Wenqiang Zheng, Bin Quan, Guangjian Gao, Puhong Zhang, Lizhu Huang

Laboratory Medicine · 07.03.2023 · 54 (2) · 130-141

DOI: 10.1093/labmed/lmac085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Laboratory Medicine, online erschienen am 15.09.2022. Verfasst von Wenqiang Zheng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, First Affiliated Hospital of Wannan Medical College, Wuhu, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Cell-Free Nucleic Acids, Tuberculosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Natural Science Research Project of Anhui Colleges and Universities, Wannan Medical College.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Non–small cell lung cancer (NSCLC) holds high metabolic tumor burden and circulating cell-free DNA (cfDNA) levels, and the relationship between metabolic tumor burden and cfDNA in NSCLC and the underlying mechanism of their interaction therein remain poorly characterized. Our aim was to evaluate the clinical value of cfDNA and metabolic tumor burden by positron emission tomography-computed tomography (PET/CT) for NSCLC differential diagnosis from tuberculosis in patients with solitary pulmonary nodules.

Methods

Metabolic tumor burden values in humans (subjects with NSCLC, subjects with tuberculosis, and healthy control subjects) and relevant mouse models were detected by preoperative 18F-fluorodeoxyglucose PET (18F-FDG PET/CT) and [3H]-2-deoxy-DG uptake, respectively. The cfDNA levels were detected by quantifying serum cfDNA fragments from the ALU (115 bp) gene using reverse transcription–polymerase chain reaction. RNA sequence was performed to determine the underlying target genes and knocked down or inhibited the target genes in vivo and in vitro to determine the mechanism therein.

Results

Metabolic tumor burden correlated with serum cfDNA levels in NSCLC subjects but not in tuberculosis subjects or healthy controls. Mouse models showed a similar phenomenon. In addition, the RNA sequence showed that glucose transporter 1 (GLU1), factor-related apoptosis ligand (FasL), caspase 8, and caspase 3 were significantly increased in NSCLC mouse tumors compared with those in tuberculosis mouse masses. Inhibiting the metabolic tumor burden by blocking or knocking down GLU1 markedly reduced the expression of FasL, the phosphorylation of caspase 8/caspase 3, and serum cfDNA levels/apoptosis percentage in vivo and in vitro. Furthermore, the use of a combination of cfDNA and metabolic tumor burden allowed better ability to distinguish NSCLC subjects from those with tuberculosis or healthy controls than either method used alone.

Conclusion

Metabolic tumor burden promotes the formation of circulating cfDNA through GLU1-mediated apoptosis in NSCLC, and the combination of cfDNA and metabolic tumor burden could be valuable for distinguishing NSCLC from tuberculosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsCell-Free Nucleic AcidsTuberculosisHumansAnimalsMicePositron Emission Tomography Computed TomographyCaspase 3Caspase 8DNA, NeoplasmPositron-Emission TomographyFluorodeoxyglucose F18

Stichwörter der Autor:innen

circulating cell-free DNAglucose transporter 1metabolic tumor burdennon–small cell lung cancertuberculosis

Substanzen

Caspase 3Caspase 8DNA, NeoplasmFluorodeoxyglucose F18Cell-Free Nucleic Acids

Autor:innen und Institutionen

  • Department of Nuclear Medicine, First Affiliated Hospital of Wannan Medical College, Wuhu, China.
  • Department of Infectious Diseases, First Affiliated Hospital of Wannan Medical College, Wuhu, China.
  • Department of Clinical Laboratory, Second Affiliated Hospital of Wannan Medical College, Wuhu, China.
  • Department of Clinical Laboratory, First Affiliated Hospital of Wannan Medical College, Wuhu, China.

Förderung

  • Natural Science Research Project of Anhui Colleges and Universities
  • Wannan Medical College

Zitieren

APA

Zheng, W., Quan, B., Gao, G., Zhang, P., & Huang, L. (2023). Combination of Circulating Cell-Free DNA and Positron Emission Tomography to Distinguish Non–Small Cell Lung Cancer from Tuberculosis. Laboratory Medicine, 54(2), 130-141. https://doi.org/10.1093/labmed/lmac085

Vancouver

Zheng W, Quan B, Gao G, Zhang P, Huang L. Combination of Circulating Cell-Free DNA and Positron Emission Tomography to Distinguish Non–Small Cell Lung Cancer from Tuberculosis. Laboratory Medicine. 2023;54(2):130-141. doi:10.1093/labmed/lmac085

BibTeX
@article{Zheng2023,
  author = {Zheng, Wenqiang and Quan, Bin and Gao, Guangjian and Zhang, Puhong and Huang, Lizhu},
  title = {Combination of Circulating Cell-Free DNA and Positron Emission Tomography to Distinguish Non–Small Cell Lung Cancer from Tuberculosis},
  journal = {Laboratory Medicine},
  year = {2023},
  volume = {54},
  number = {2},
  pages = {130--141},
  doi = {10.1093/labmed/lmac085}
}
Kostenlos starten →